



ImmunoGen Announces Webcast of Panel Discussion at Upcoming Cowen 42nd Annual Health Care Conference

February 23, 2022

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 23, 2022-- [ImmunoGen, Inc.](#) (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will participate in the ovarian cancer panel discussion at the upcoming Cowen 42nd Annual Health Care Conference. The panel is scheduled for March 9, 2022 from 12:50 – 1:50pm ET.

A webcast of the panel will be accessible through the "Investors and Media" section of the Company's website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220223005063/en/): <https://www.businesswire.com/news/home/20220223005063/en/>

INVESTOR RELATIONS AND MEDIA CONTACTS

ImmunoGen
Courtney O'Konek
781-895-0600
courtney.okonek@immunogen.com

OR

FTI Consulting
Robert Stanislaro
212-850-5657
robert.stanislaro@fticonsulting.com

Source: ImmunoGen, Inc.